Science Explorer Back to mapMap
Discussion
Researcher · Eureka Therapeutics (United States) · United States

Jingyi Xiang

Jingyi Xiang publishes mostly in Molecular Biology, Oncology and Immunology, on topics such as CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research and Immunotherapy and Immune Responses.

ORCID 0000-0001-9675-6520 OpenAlex
World rank
#1,232,660
of 7,710,434 ranked researchers
Rank in United States
#394,292
of 1,627,098
Works
44
Citations
1.6k
Citations per work
36.2
h-index
11
i10-index 11Top 71% in Molecular Biology
Jingyi Xiang

What does Jingyi Xiang research?

Jingyi Xiang's work is mostly in Medicine (33%), Biochemistry, Genetics and Molecular Biology (21%), Immunology and Microbiology (11%).

Health Sciences: 15 works · 33.3% of their workMedicine: 15 works · 33.3% of their workOncology: 8 works · 18.2% of their workRadiology, Nuclear Medicine and Imaging: 5 works · 10.6% of their workPhysiology: 2 works · 4.5% of their workEverything else: 14 works · 31.9% of their workLife Sciences: 14 works · 31.8% of their workBiochemistry, Genetics and Molecular Biology: 9 works · 21.2% of their workMolecular Biology: 9 works · 21.2% of their workImmunology and Microbiology: 5 works · 10.6% of their workImmunology: 5 works · 10.6% of their workPhysical Sciences: 1 works · 3.0% of their workEngineering: 1 works · 3.0% of their workAerospace Engineering: 1 works · 3.0% of their workTHEIR WORKJingyi Xiang44works
Life Sciences32%Physical Sciences3%Health Sciences33%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine1533.3%
  2. Everything else1431.9%
    1. Biochemistry, Genetics and Molecular Biology921.2%
    2. Immunology and Microbiology510.6%
    1. Engineering13.0%
  1. 1Molecular Biology21% of their works
  2. 2Oncology18% of their works
  3. 3Immunology11% of their works
  4. 4Radiology, Nuclear Medicine and Imaging11% of their works
  5. 5Physiology4% of their works
  6. 6Aerospace Engineering3% of their works

Research topics

Which keywords describe Jingyi Xiang's research?

The keywords of their largest research topics: Cancer Immunotherapy, CAR T Cells, Chimeric Antigen Receptor, Glycosylation, Fc Receptors, Therapeutic Antibodies, Dendritic Cells and Immunity.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 18 words, with their numbers
  1. Cancer Immunotherapy142 topics
  2. CAR T Cells101 topic
  3. Chimeric Antigen Receptor101 topic
  4. Glycosylation93 topics
  5. Fc Receptors61 topic
  6. Therapeutic Antibodies61 topic
  7. Dendritic Cells41 topic
  8. Immunity41 topic
  9. Gene Therapy21 topic
  10. Mammalian Cells21 topic
  11. Piezo121 topic
  12. Piezo221 topic
  13. RNA methylation21 topic
  14. Recombinant Protein21 topic
  15. Viral Vectors21 topic
  16. m6A-seq21 topic
  17. Cancer11 topic
  18. Glycans11 topic

Where does Jingyi Xiang work?

Jingyi Xiang's main affiliation in the publication record is Eureka Therapeutics (United States), United States.

How many publications and citations does Jingyi Xiang have?

OpenAlex counts 44 works and 1,593 citations for Jingyi Xiang, an h-index of 11, ranking #1,232,660 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Jingyi Xiang. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.